New combo therapy aims to shrink head and neck tumors
NCT ID NCT06727565
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 27 times
Summary
This study tests whether adding an experimental drug (domvanalimab) to a standard immunotherapy (zimberelimab) plus chemotherapy works better than the standard immunotherapy plus chemotherapy alone for people with head and neck cancer that has spread or come back. About 100 adults who have not had prior treatment for this stage of cancer will take part. The main goals are to see if the combination shrinks tumors and delays cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alfred Health
Melbourne, Victoria, 3004, Australia
-
Barts Health NHS Foundation Trust
London, EC1A 7BE, United Kingdom
-
CHU de Bordeaux
Pessac, 33604, France
-
Chang Gung Memorial Hospital, Linkou
Taoyuan District, 33308, Taiwan
-
China Medical University Hospital
Taichung, 40402, Taiwan
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
Guangxi Medical University Cancer Hospital
Nanning, 530012, China
-
Hospital Universitario Virgen del Rocio
Seville, 41013, Spain
-
ICON Cancer Center
Kurralta Park, South Australia, 5037, Australia
-
Istituto Nazionale Tumori Fondazione G. Pascale
Naples, 80131, Italy
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, 80756, Taiwan
-
Monash Health
Clayton, Victoria, 3168, Australia
-
Sarawak General Hospital
Sarawak, 93586, Malaysia
-
Shanghai East Hospital
Shanghai, 200120, China
-
Sichuan Cancer Hospital
Chengdu, 610040, China
-
Siteman Cancer Center
St Louis, Missouri, 63110, United States
-
Taipei Veterans General Hospital
Taipei, 11217, Taiwan
-
Tennessee Oncology, PLLC - Greco-Hainsworth Centers for Research
Nashville, Tennessee, 37203, United States
-
The Royal Marsden NHS Foundation Trust
London, SW10 9NH, United Kingdom
-
The University of Texas, MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, 430030, China
-
Westmead Hospital
Sydney, New South Wales, 2145, Australia
-
Zhejiang Cancer Hospital
Hangzhou, 310005, China
Conditions
Explore the condition pages connected to this study.